Multiple Sclerosis, Relapsing-Remitting Clinical Trial
— CIRMSOfficial title:
A Non-interventional Observation Study to Evaluate Immune Responses Following Seasonal Influenza Vaccine in Participants With Relapsing Multiple Sclerosis Treated With Cladribine Tablets
NCT number | NCT05019248 |
Other study ID # | 2021-1474 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | September 1, 2020 |
Est. completion date | April 30, 2022 |
The primary objective of this study is to characterize the antibody response to seasonal influenza vaccine, in patients with active RRMS, treated with cladribine, compared to control individuals with basic immunomodulatory treatment. Serum antibody titers against the respective pathogen will be assessed prior to and 6 to 8 months following vaccination.
Status | Recruiting |
Enrollment | 260 |
Est. completion date | April 30, 2022 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: 1. Signed informed consent form (ICF) 2. Age 18 to 60 years old (inclusive) as of the date the ICF is signed 3. Diagnosis of RRMS according to the revised McDonald criteria 4. EDSS score of 0.0 to 7.0 (inclusive) 5. In case of participants who are subjected to influenza vaccination by the treating physicians prior to cladribine the first or second cycle of cladribine (cohort 1 + cohort 3), this should be performed at least 4 to 6 weeks before the start of cladribine. Definition of control group: Patients with active RRMS treated with cladribine will be compared to sex and age matched control individuals, with RRMS under basic treatment either with interferon beta, glatiramer acetate, dimethyl fumarate or teriflunomide, who provide sample material prior to and 6 to 8 months after routine seasonal influenza vaccination during the same period. Exclusion Criteria: 1. Previous treatment with B-cell targeted therapies (e.g., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab) 2. Any previous treatment with alemtuzumab, cladribine, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation 3. Medical, psychiatric, cognitive, or other conditions that, in the investigator's opinion, compromise the patient's ability to understand the patient information, to give informed consent, or to complete the study 4. Patients that receive immunosuppressive treatment for diseases other than MS or that receive long-term corticosteroid treatment 5. Patients that received apheresis procedures 6 weeks prior to vaccination or in-between vaccination and DMT initiation 6. Systemic high dose corticosteroid therapy within 6 weeks prior to vaccination or in-between vaccination and DMT initiation 7. Patients with verified infection by human-immunodeficiency-virus or hepatitis-c-virus 8. Patients with major impairment of the blood coagulation system including therapy with anticoagulants 9. Patients with known chicken egg allergy |
Country | Name | City | State |
---|---|---|---|
Germany | Medical Faculty, Heinrich-Heine-University | Duesseldorf | Northrhine-Westphalia |
Lead Sponsor | Collaborator |
---|---|
Heinrich-Heine University, Duesseldorf |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion who achieve seroprotection | The capacity of influenza vaccine to elicit a measurable immune response (immunogenicity) when it is administered (i) shortly (at least 4-6 weeks) before cladribine initiation (cohort 1), (ii) 3 to 4 months after cladribine initiation (cohort 2) (iii) shortly (at least 4-6 weeks) before second cladribine administration (cohort 3) and (iv) in patients who have already received the second cycle of cladribine tablets (3 to 4 months after second cycle; cohort 4), compared to RRMS patients treated with basic DMTs (cohort 5). Efficacy is measured as proportion of patients who achieve seroprotection (specific hemagglutination inhibition (HI) titers > 1:40)). | 6 months | |
Secondary | Fraction with 2-fold increase of HI titers | Proportion of patients who achieve a 2-fold increase in specific HI titers at 6 to 8 months post-immunization | 6 months | |
Secondary | Fraction with 4-fold increase of HI titers | Proportion of patients who achieve a 4-fold increase in specific HI titers at 6 months post-immunization | 6 months | |
Secondary | Seroconversion rate | Proportion of patients with seroconversion (i.e., a pre-vaccination antibody titer < 10 and a post-vaccination HI titer > 40) | 6 months | |
Secondary | Mean antibody titers | Geometric mean antibody titers (GMTs) and geometric mean antibody ratios (GMRs, post-vaccination:pre-vaccination) prior and 6 months after vaccination | 6 months | |
Secondary | Cellular immune responses | Flow cytometry analysis, which will include (but is not limited to) the following cells: Total B cells (CD19 positive), B-cell subsets, e.g., memory B cells, naïve B cells, plasma cells; Total T cell (CD3 positive) and T cell subsets, e.g. T helper cells, cytotoxic lymphocyte T cells | 6 months | |
Secondary | Serum immunoglobulin subtypes | Analysis of quantitative Ig levels (including total Ig, IgG, IgG subtypes, IgM, and IgA) | 6 months | |
Secondary | Influenza infections | Incidence of infections caused by influenza | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02861014 -
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
|
Phase 3 | |
Terminated |
NCT01435993 -
Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis
|
Phase 1 | |
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Completed |
NCT02410200 -
Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
|
Phase 2 | |
Completed |
NCT03975413 -
Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis
|
||
Completed |
NCT05080270 -
Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis
|
Early Phase 1 | |
Completed |
NCT01116427 -
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT01108887 -
An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.
|
N/A | |
Completed |
NCT01141751 -
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy
|
N/A | |
Completed |
NCT00097331 -
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT01909492 -
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
|
||
Completed |
NCT04121221 -
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
|
Phase 3 | |
Not yet recruiting |
NCT05290688 -
Cellular microRNA Signatures in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT04880577 -
Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04528121 -
Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT04002934 -
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04580381 -
Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
|
||
Completed |
NCT00071838 -
Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT03910738 -
TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis
|
Phase 2 |